Thesium chinense Turcz. alleviates antibiotic-associated diarrhea in mice by modulating gut microbiota structure and regulating the EGFR/PI3K/Akt signaling pathway.
10.12122/j.issn.1673-4254.2025.02.09
- Author:
Haonan XU
1
;
Fang ZHANG
2
;
Yuying HUANG
3
;
Qisheng YAO
4
;
Yueqin GUAN
4
;
Hao CHEN
1
Author Information
1. College of Animal Science, Anhui Science and Technology University, Fengyang 233100, China.
2. College of Food Engineering, Anhui Science and Technology University, Fengyang 233100, China.
3. College of Life and Health Sciences, Anhui Science and Technology University, Fengyang 233100, China.
4. Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd., Chuzhou 239000, China.
- Publication Type:Journal Article
- Keywords:
16S rRNA gene sequencing;
EGFR/PI3K/Akt signaling pathway;
Thesium chinense Turcz.;
antibiotic-associated diarrhea;
molecular dynamics simulation;
network pharmacology
- MeSH:
Animals;
Gastrointestinal Microbiome/drug effects*;
Signal Transduction/drug effects*;
Mice;
ErbB Receptors/metabolism*;
Proto-Oncogene Proteins c-akt/metabolism*;
Diarrhea/drug therapy*;
Phosphatidylinositol 3-Kinases/metabolism*;
Anti-Bacterial Agents/adverse effects*;
Drugs, Chinese Herbal/therapeutic use*;
Molecular Docking Simulation
- From:
Journal of Southern Medical University
2025;45(2):285-295
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the therapeutic mechanism of Thesium chinense Turcz. (TCT) for antibiotic-associated diarrhea (AAD).
METHODS:Network pharmacology, KEGG pathway enrichment analysis and molecular docking were used to identify the shared targets and genes of TCT and AAD, the key signaling pathways and the binding between the active components in TCT and the core protein targets. In a Kunming mouse model of AAD established by intragastric administration of lincomycin hydrochloride, the effects of daily gavage of 1% carboxymethyl cellulose sodium or TCT gel solutions at 1.5 g/kg and 3 g/kg (n=10) on body weight and diarrhea were observed. HE staining, ELISA, 16S rRNA sequencing, and Western blotting were used to examine pathologies, expression levels of IL-6 and TNF-α, changes in gut microbiota, and protein expressions of EGFR, p-EGFR, PI3K, p-PI3K, Akt, and p-Akt in the colon tissues of the mice.
RESULTS:We identified a total of 66 active components of TCT and 68 core targets including EGFR, STAT3 and PIK3CA. KEGG pathway enrichment analysis suggested that the therapeutic effects of TCT was mediated primarily through the PI3K/Akt signaling pathway. Molecular docking showed that EGFR had the highest binding affinity with coniferin, and the EGFR-coniferin complex maintained a stable conformation at 10 ns, whose stability was also confirmed by Gibbs free energy analysis. In the mouse models of AAD, treatment with TCT significantly improved colonic tissue morphology, decreased colonic levels of TNF-α and IL-6, increased gut microbiota diversity, and modulated the relative abundances of the key genera including Lactobacillus and Bacteroides. TCT treatment also markedly reduced protein expressions of p-EGFR, p-PI3K and p-Akt in the colon tissues of the mice.
CONCLUSIONS:TCT can alleviate AAD in mice by modulating gut microbiota composition, regulating the EGFR/PI3K/Akt signaling pathway, and reducing TNF‑α and IL-6 expressions.
